Stocks and Investing
Stocks and Investing
Wed, May 1, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Sykes Maintained (TXG) at Strong Sell with Decreased Target to $26 on, May 1st, 2024
Matthew Sykes of Goldman Sachs, Maintained "10x Genomics, Inc." (TXG) at Strong Sell with Decreased Target from $30 to $26 on, May 1st, 2024.
Matthew has made no other calls on TXG in the last 4 months.
There are 3 other peers that have a rating on TXG. Out of the 3 peers that are also analyzing TXG, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Matthew
- Kyle Mikson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $50 on, Monday, April 29th, 2024
- Justin Bowers of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $55 on, Thursday, April 18th, 2024
- Luke Sergott of "Barclays" Maintained at Buy with Decreased Target to $45 on, Wednesday, April 10th, 2024
Contributing Sources